Navigation Links
Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
Date:1/25/2008

://www.clinicaltrials.gov (search for Catalyst).

Patrick J. McEnany, Chief Executive Officer of Catalyst, commented: "We are very pleased to announce the start of active enrollment in our study of CPP-109 as a potential treatment for cocaine addiction. We expect to add more clinical trial sites to the 10 previously disclosed in order to complete the trial as soon as possible. We anticipate initial top-line results from this trial to be available by year-end."

Douglas Winship, Catalyst's Vice President of Regulatory Operations, stated: "Vigabatrin has previously shown the potential to be a safe and effective non-addictive drug treatment for cocaine and methamphetamine addiction in a Phase II double-blind, placebo-controlled trial and two pilot studies conducted in Mexico. We are excited to now evaluate the therapeutic benefit of CPP-109 in cocaine-addicted patients enrolled in a large, double- blind, placebo-controlled trial conducted in the U.S. under our sponsorship. There are currently no prescription drugs approved for the treatment of this population. As a result, drug therapies are desperately needed which can improve abstinence achievement rates of behavioral therapy administered by addiction treatment specialists, and reduce recidivism. We have worked diligently with regulatory authorities and the independent institutional review boards at each of the clinical sites where our trial will be conducted to be able to finalize and implement our protocol for this trial."

On December 7, 2007, Catalyst announced positive initial top-line results from a 103-patient, investigator-initiated Phase II double-blind, placebo- controlled trial, in which vigabatrin met its primary efficacy endpoint of abstinence during the last weeks of treatment for cocaine addiction. Additional results of this study will be reported when they become available.

About CPP-109

CPP-109 works by inhibiting an enzyme that normally breaks down gamma aminobuty
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
3. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
4. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
7. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
8. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
9. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
10. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
11. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014 InVivo Therapeutics Holdings Corp. ... is revolutionizing spinal cord injury (SCI) treatment with ... to outperform in tissue regrowth in the spinal cord ... from an FDA approved polymer, the scaffold ultimately breaks ... to the human body. NVIV has recently attracted significant ...
(Date:10/22/2014)... Oct. 22, 2014 WHEN: Wednesday, October 29, ... registration available at: http://bit.ly/1yStiU9 SPEAKERS: ... and Visionary Innovation Research Group Senior Research ... self-assembling materials, nanobots and flexible electronics are ... transform our lives in the coming decades. ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
Breaking Medicine Technology:InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... Two new analyses of observational,data presented at today,s ... patients receiving transfusions when,erythropoiesis- stimulating agents (ESAs) treatment ... 11 grams per deciliter (g/dL) of blood,compared with ... prior to ESA,treatment. In addition, wide variability in ...
... of innovative,Therapeutics Development Initiative, NEW YORK, Jan. 31 ... it takes to speed delivery of transformative,treatments and a ... Parkinson,s Research has awarded up to $3 million in ... new PD treatments,closer to the clinic. The awards were ...
Cached Medicine Technology:Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents 2Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents 3Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents 4Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents 5Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 2Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 3
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... sisters in high school have developed ways to measure ... use electronic stethoscopes, which electronically amplify body sounds, to ... heartbeats. Ilina, a senior at Port Huron Northern ... to detect early lung damage in people exposed to ... one breath cycle each from 16 smokers, 25 nonsmokers ...
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... 17, 2010)Healthcare personnel influenza immunization rates have remained ... Control and Prevention (CDC) and other leading healthcare ... vaccines. Experts say these levels are perilous. Increasing ... deaths by 40 percent. Three ...
... JAZZ ) announced today that Robert Myers , the company,s President, will present at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24, 2010 ... ... ... ...
... to address Illinois with his ideas on how to reform the state budget, Little City Foundation last week spoke to numerous legislators, ... , ... , , ... ...
... , ... , ... ... March 16 "Now is the time to get this done. Teamster members have solid health care coverage, but the outrageous cost of insurance is hurting our employers and dragging down the economy. ...
... Va. , March 16 Star Scientific, Inc. (Nasdaq: ... Securities and Exchange Commission. The company reported net sales of $0.7 ... sales for the previous year.  Cash and cash equivalents at year-end 2009 ... year-end 2008. The net loss for 2009 totaled approximately $(22.8) million ...
... What: To help speed the translation of scientific discoveries ... Heart, Lung, and Blood Institute (NHLBI) of the National ... ( http://www.benchtobassinet.net/ ). This program, which involves several major ... the March 23 edition of the Journal of ...
Cached Medicine News:Health News:Strategies increase health-care worker vaccination rates -- protecting patients 2Health News:Strategies increase health-care worker vaccination rates -- protecting patients 3Health News:Strategies increase health-care worker vaccination rates -- protecting patients 4Health News:Jazz Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference 2Health News:Little City Foundation Battles for Rights of Individuals with Disabilities in Springfield and Meets with Legislators Day Before Governor's Budget Address 2Health News:Little City Foundation Battles for Rights of Individuals with Disabilities in Springfield and Meets with Legislators Day Before Governor's Budget Address 3Health News:Little City Foundation Battles for Rights of Individuals with Disabilities in Springfield and Meets with Legislators Day Before Governor's Budget Address 4Health News:Little City Foundation Battles for Rights of Individuals with Disabilities in Springfield and Meets with Legislators Day Before Governor's Budget Address 5Health News:Little City Foundation Battles for Rights of Individuals with Disabilities in Springfield and Meets with Legislators Day Before Governor's Budget Address 6Health News:Little City Foundation Battles for Rights of Individuals with Disabilities in Springfield and Meets with Legislators Day Before Governor's Budget Address 7Health News:Little City Foundation Battles for Rights of Individuals with Disabilities in Springfield and Meets with Legislators Day Before Governor's Budget Address 8Health News:Little City Foundation Battles for Rights of Individuals with Disabilities in Springfield and Meets with Legislators Day Before Governor's Budget Address 9Health News:Little City Foundation Battles for Rights of Individuals with Disabilities in Springfield and Meets with Legislators Day Before Governor's Budget Address 10Health News:Little City Foundation Battles for Rights of Individuals with Disabilities in Springfield and Meets with Legislators Day Before Governor's Budget Address 11Health News:Hoffa on Health Care Reform: 'Time to Get This Done' 2Health News:Hoffa on Health Care Reform: 'Time to Get This Done' 3Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 2Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 3Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 4Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 5Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 6Health News:Bench to bassinet program seeks congenital heart disease treatments 2
... purified non-ionic fraction of agar. Forms gel ... concentrations. Can be mounted on microscope slides ... elastic and durable and show little or ... or lipoprotein dyes. Contaminants: ash: ...
... Certified PCR agarose is recommended for separations ... agarose forms gels that are easy to ... gel percentages, which minimizes the risk of ... genetic quality tested (GQT) products with similar ...
... Agarose-HR™ High Resolution - ... from 50 to 1000 ... for sizing PCR fragments, ... by restriction enzyme digestion, ...
The reading of agglutinations process in Diana Reader is by image treatment which allows great sensitivity....
Medicine Products: